Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis (ACR Convergence 2025) - Sep 15, 2025 - Abstract #2466; Pres time: Oct 28, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; P2 | "Safety analysis of enrolled pts indicated overall similar safety profiles between zeto dosed at 30 mg and 60 mg, and these findings are consistent with previous studies of zeto in LN. Preliminary efficacy data from a treatment evaluable population with Class III/IV ± V LN in the PALIZADE trial offer encouraging activity in pts receiving a 60 mg dose of zeto."
Clinical • P2b data • Cardiovascular • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Richard Furie1; Neel Anand2; Shraddha Desai3; Eric Lowe4; Tony Muchamuel3; Kiruthi Palaniswamy2; Rachel Peterson2; Kathryn Ray2; Zung To2; Jennifer Whang2; Richard Leff5
|